JPRN-UMIN000013067已完成1 期
Phase I/II trial of subcutaneous bortezomib plus lenalidomide combined with dexamethasone combination therapy for relapsed or refractory multiple myeloma patients - FBMTG-sVRd14
Fukuoka Blood and Marrow Transplantation Group0 个研究点目标入组 50 人开始时间: 2014年2月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Peripheral neuropathy and neuropathic pain >=Grade 2(CTCAE ver.4.0). 2) Those who can not receive bortezomib subcutaneously at a dose of 1.3 mg/m2 3) History of hypersensitivity to lenalidomide, bortezomib, dexamethasone, mannitol or boron. 4) Nonsecretory multiple myeloma, solitary plasmacytoma, plasma cell leukemia or POEMS syndrome. 5) Known human immunodeficiency virus (HIV) infection or active hepatitis A, B or C. 6) Serious concurrent uncontrolled medical disorder. (hepatic dysfunction, renal failure, cardiac dysfunction, pulmonary dysfunction diabetes, hypertension and infectious diseases) 7) History of active malignancy during the past 5 years 8) Psychoneurotic disorder, depression state or history 9) Pregnant or lactating female 10) Patients with pneumonia, pulmonary fibrosis or bilateral interstitial abnormalities. 11) Those who are considered as inappropriate to register by attending physicians
研究者
相似试验
撤回
2 期
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceMultiple MyelomaNCT01647165National Cancer Institute (NCI)
已完成
1 期
Phase I/II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly VRd-21) for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM)Proteasome inhibitor and immunomodulatory drug pre-treated relapsed and/or refractory multiple myeloma after two or more prior lines of chemotherapyJPRN-UMIN000013169agoya City University Hospital30
进行中（未招募）
不适用
Randomized phase II study of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in elderly patients with newly diagnosed multiplemyelomaKCT0004508Samsung Medical Center126
已完成
2 期
(C-SHOT1601)Phase II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly BLd) for elderly or transplant-ineligible patients with untreated symptomatic multiple myelomaElderly or transplant-ineligible patients with untreated symptomatic multiple myelomaJPRN-UMIN000022008agoya City University Hospital Division of Hematology & Oncology30
已完成
不适用
Phase II study of bortezomib maintenance therapy for multiple myeloma patientsMultiple MyelomaJPRN-UMIN000013912ational Hospital Organization Disaster Medical Center of Japan96